On the whole, we first demonstrated the significant upregulation of vimentin in metastatic melanoma compared to primary cases by proteomics and carried out the clinical verification to evalute whether vimentin is a potential biomarker for predicting the metastasis in melanoma patients. Here, VIM is linked to metastatic melanoma.